The results of two large multicentric, observational and cross-sectional studies (the DIAINFORM study and BALI study) reflecting routine clinical practice for insulin treatment in type 2 diabetes mellitus in the Czech Republic were published recently. In this commentary, we analyze these results and compare them with the findings of similar studies conducted in other countries within the last decade. The analysis focuses on achievement of glycated hemoglobin goals, insulin dosage and frequency of hypoglycemia.

2nd Department of Internal Medicine 3rd Faculty of Medicine Center for Research in Diabetes Metabolism and Nutrition Charles University Prague Czech Republic

Department of Internal Medicine 2nd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Brož J, Janíčková Žďárská D, Urbanová J, et al. Current level of glycemic control and clinical inertia in subjects using insulin for the treatment of type 1 and type 2 diabetes in the Czech Republic and the Slovak Republic: results of a multinational, multicentre observational survey (DIAINFORM) Diabetes Ther. 2018;9:1897–1906. doi: 10.1007/s13300-018-0485-2. PubMed DOI PMC

Brož J, Janíčková Ždárská D, Štěpánová R, et al. Addition of basal insulin to oral antidiabetic agents in patients with inadequately controlled type 2 diabetes leads to improved HbA1c levels: metabolic control, frequency of hypoglycemia, and insulin titration analysis as results of a prospective observational study (BALI Study) Diabetes Ther. 2019;10(2):663–672. doi: 10.1007/s13300-019-0584-8. PubMed DOI PMC

Selvin E, Parrinello ChM, Daya N, Bergenstal RM. Trends in insulin use and diabetes control in the US: 1988–1994 and 1999–2012. Diabetes Care. 2016;39(3):e33–e35. doi: 10.2337/dc15-2229. PubMed DOI PMC

Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol. 2014;80:47–56. doi: 10.1111/cen.12119. PubMed DOI

Shan S, Gu L, Lou Q. Evaluation of glycemic control in patients with type 2 diabetes mellitus in Chinese communities: a cross-sectional study. Clin Exp Med. 2017;17(1):79–84. doi: 10.1007/s10238-015-0406-x. PubMed DOI

Meneghini LF, Mauricio D, Orsi E, et al. The diabetes unmet need with basal insulin evaluation (DUNE) study in type 2 diabetes: achieving HbA(1c) targets with basal insulin in a real-world setting. Diabetes Obes Metab. 2019;21(6):1429–1436. doi: 10.1111/dom.13673. PubMed DOI PMC

American Diabetes Association Standards of medical care in diabetes—2017: summary of revisions. Diabetes Care. 2017;40:S4–S5. doi: 10.2337/dc17-S003. PubMed DOI

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) Diabetes Care. 2014;37(10):2755–2762. doi: 10.2337/dc14-0991. PubMed DOI

Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study) Diabetes Obes Metab. 2015;17(8):734–741. doi: 10.1111/dom.12482. PubMed DOI

Riebenfeld D, Spirk D, Mathis A. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain. Swiss Med Wkly. 2015;145:w14114. doi: 10.4414/smw.2015.14114. PubMed DOI

Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–511. doi: 10.1016/j.diabet.2017.06.003. PubMed DOI

Haluzik M, Kretowski A, Strojek K, et al. Perspectives of patients with insulin-treated type 1 and type 2 diabetes on hypoglycemia: results of the HAT observational study in Central and Eastern European Countries. Diabetes Ther. 2018;9:727–741. doi: 10.1007/s13300-018-0388-2. PubMed DOI PMC

Blonde L, Meneghini L, Peng XV. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther. 2018;9(3):1347–1358. doi: 10.1007/s13300-018-0413-5. PubMed DOI PMC

Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155–1164. doi: 10.1111/dom.12927. PubMed DOI PMC

Chien MN, Chen YL, Hung YJ, et al. Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2016;7(6):881–888. doi: 10.1111/jdi.12532. PubMed DOI PMC

Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–1288. doi: 10.2337/diacare.28.6.1282. PubMed DOI

Riebenfeld D, Spirk D, Mathis A, et al. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain. Swiss Med Wkly. 2015;145(5):w14114. PubMed

Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study)